ASH 2019, Sonja Loges et al

9 December 2019, Orlando, USA

Durable responses observed in elderly AML patients ufit for intencive chemotherapy with First-in-Class selective AXL inhibitor bemcentinib (BGB324) in combination with LDAC: Phase II open-label study.